← Back to Search

Corticosteroid

Triamcinolone for Acne Rosacea

Phase 2

Waitlist Available

Led By Jennifer N Choi, MD

Research Sponsored by Northwestern University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 weeks

Awards & highlights

Study Summary

This trial will test if a steroid cream can prevent skin reactions caused by a cancer drug. Participants will use the cream twice a day for 6 weeks.

Eligible Conditions

Acneiform Rash
Acne Rosacea

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

% of Participants With Grade 2 Rash or Higher

Secondary outcome measures

Change in Quality of Life Using FACT-EGFRI 18 Quality of Life Assessment

Number of Participants in the Treatment and Control Group Who Adhere to Their Chemotherapy Regimen Determined by Whether Patients Discontinue Their Chemotherapy Regimen or Continue Their Full Course of Treatment

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: TriamcinoloneExperimental Treatment1 Intervention

Patients in the Triamcinolone group will be applying Triamcinolone 0.1% cream daily to their face, chest, and upper back, in addition to adhering to the same daily moisturizer and sunscreen regimen of the Control group. Erlotinib, cetuximab, panitumumab, or afatinib will be administered concomitantly as standard of care treatment.

Group II: ControlActive Control1 Intervention

Patients in Control group will be instructed to follow a daily moisturizer and sunscreen regimen. Erlotinib, cetuximab, panitumumab, or afatinib will be administered as standard of care treatment.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Triamcinolone

2016

Completed Phase 4

~1220

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor

1,584 Previous Clinical Trials

917,751 Total Patients Enrolled

Jennifer N Choi, MDPrincipal InvestigatorNorthwestern University

2 Previous Clinical Trials

16 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open slots for participants in this experiment?

"That is correct, the clinical trial is recruiting patients at this time. According to the information on clinicaltrials.gov, the study was originally posted on February 16th, 2017 and was last updated on June 7th, 2022. The research team is hoping to find 84 willing participants from 1 location."

Answered by AI

What conditions does Triamcinolone typically treat?

"Ulcerative colitis is most often treated with Triamcinolone. However, this medication can also be used to help patients manage a variety of other conditions such as hand, brain, and dermatologic disorders."

Answered by AI

How many people have signed up for this clinical trial thus far?

"The most recent update on clinicaltrials.gov indicates that this study is still looking for recruits. The trial was posted on February 16th, 2017 and the 84 patients are needed at a single site."

Answered by AI

Is Triamcinolone generally considered to be harmful for human health?

"While there is some evidence that Triamcinolone is safe, it only received a score of 2 because Phase 2 trials have yet to demonstrate efficacy."

Answered by AI

Are there other examples of Triamcinolone being used in medical research?

"Out of the 48 active studies on Triamcinolone, 9 have reached Phase 3 clinical trials. The focus of most research is in Columbia, Missouri; however, there are a total of 82 medical centres running these tests across the United States."

Answered by AI

Recent research and studies

Supportive Care in CancerJournal

A Proposed EGFR Inhibitor Dermatologic Adverse Event-specific Grading Scale from the MASCC Skin Toxicity Study Group

Lacouture, Mario E., Michael L. Maitland, Siegfried Segaert, Ann Setser, Robert Baran, Lindy P. Fox, Joel B. Epstein, et al.. 2010. “A Proposed EGFR Inhibitor Dermatologic Adverse Event-specific Grading Scale from the MASCC Skin Toxicity Study Group”. Supportive Care in Cancer. Springer Science and Business Media LLC. doi:10.1007/s00520-009-0744-x.

Supportive Care in CancerJournal

A Proposed EGFR Inhibitor Dermatologic Adverse Event-specific Grading Scale from the MASCC Skin Toxicity Study Group

clinicaltrials.govStudy

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

Jennifer Nam Choi, MD 2017. "A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03115567.